Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Immune activation and paediatric HIV-1 disease outcome

Immune activation and paediatric HIV-1 disease outcome Downloaded from http://journals.lww.com/co-hivandaids by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/04/2020 REVIEW URRENT Immune activation and paediatric HIV-1 PINION disease outcome a,b,c a,b a,b Julia M. Roider , Maximilian Muenchhoff , and Philip J.R. Goulder Purpose of review The paediatric HIV epidemic is changing. Over the past decade, new infections have substantially reduced, whereas access to antiretroviral therapy (ART) has increased. Overall this success means that numbers of children living with HIV are climbing. In addition, the problems observed in adult infection resulting from chronic inflammation triggered by persistent immune activation even following ART mediated suppression of viral replication are magnified in children infected from birth. Recent findings Features of immune ontogeny favour low immune activation in early life, whereas specific aspects of paediatric HIV infection tend to increase it. A subset of ART-naı¨ve nonprogressing children exists in whom normal CD4 cell counts are maintained in the setting of persistent high viremia and yet in the context of low immune activation. This sooty mangabey-like phenotype contrasts with nonprogressing adult infection which is characterized by the expression of protective HLA class I molecules and low viral load. The particular factors contributing to raised or lowered immune activation in paediatric infection, which ultimately influence disease http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV & AIDS Wolters Kluwer Health

Immune activation and paediatric HIV-1 disease outcome

Loading next page...
 
/lp/wolters-kluwer-health/immune-activation-and-paediatric-hiv-1-disease-outcome-eIhZSZW3R7

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0000000000000231
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/co-hivandaids by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/04/2020 REVIEW URRENT Immune activation and paediatric HIV-1 PINION disease outcome a,b,c a,b a,b Julia M. Roider , Maximilian Muenchhoff , and Philip J.R. Goulder Purpose of review The paediatric HIV epidemic is changing. Over the past decade, new infections have substantially reduced, whereas access to antiretroviral therapy (ART) has increased. Overall this success means that numbers of children living with HIV are climbing. In addition, the problems observed in adult infection resulting from chronic inflammation triggered by persistent immune activation even following ART mediated suppression of viral replication are magnified in children infected from birth. Recent findings Features of immune ontogeny favour low immune activation in early life, whereas specific aspects of paediatric HIV infection tend to increase it. A subset of ART-naı¨ve nonprogressing children exists in whom normal CD4 cell counts are maintained in the setting of persistent high viremia and yet in the context of low immune activation. This sooty mangabey-like phenotype contrasts with nonprogressing adult infection which is characterized by the expression of protective HLA class I molecules and low viral load. The particular factors contributing to raised or lowered immune activation in paediatric infection, which ultimately influence disease

Journal

Current Opinion in HIV & AIDSWolters Kluwer Health

Published: Mar 1, 2016

There are no references for this article.